George Mikhaeel is a Professor of Radiation Oncology at King’s College London and Consultant Clinical Oncologist at Guy’s & St Thomas’ NHS Foundation Trust since 2001. He specialises in the treatment of lymphoma with both chemotherapy and radiotherapy and has extensive experience in advanced radiotherapy techniques for haematological malignancies.

Professor Mikhaeel’s research has resulted in new ways of treating lymphoma patients with radiotherapy, harnessing the benefits of advances in radiotherapy technology and advances in imaging. An example of new treatments is combining an innovative arc technique and deep inspiration breath-hold (DIBH) with image-guided delivery of treatment to improve the accuracy of targeting radiation and reduce dose to healthy tissues.

His clinical practice is focused only on haematological malignancies which are less common and require a high level of specialisation and substantial clinical experience, having practised in this field for more 20 years. Professor Mikhaeel has lectured in more than 15 countries and has numerous publications in the field including four influential international guidelines.

He is a founding member of the International Lymphoma Radiation Oncology Group (ILROG) and a member of its steering and executive committees. Professor Mikhaeel also chairs the haematology track for the American Society of Radiation Oncology (ASTRO) annual meeting scientific committee and a reviewer for the European Society of Radiation Oncology (ESTRO). Nationally, he is the chair of the UK Lymphoma Radiotherapy Group (UK-LRG) steering committee.

• Radiotherapy
• Chemotherapy

• Haematological malignancies

Dr Kristeleit completed his undergraduate studies at the Universities of Bonn (Germany), Lausanne (Switzerland) and Barts and The London School of Medicine. He has a first class medical degree from Bonn University and performed his post graduate and specialist training in London teaching hospitals. He spent four years as an AVON Clinical Research Fellow at the Breakthrough Breast Cancer Research Centre investigating novel targets in familial breast cancer. He was appointed as a Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust in 2009.

He has a special interest in breast cancer and Acute Oncology. He provides the medical oncology service for breast cancer at Queen Elizabeth and Queen Mary's hospitals and is currently the lead clinician for Acute Oncology in the South East London Accountable Cancer Network. Dr Kristeleit has a keen research interest in the role of novel therapies for breast cancer. He is an investigator on numerous clinical trials for breast cancer and chairs the oncology research committee at Guy's and St Thomas'.

He gives regular lectures for the University of London and has been invited to speak at national conferences and international meetings. He specializes in the treatment of early and advanced breast cancer.

Vinod Mullassery is a Consultant Clinical Oncologist at Guys and St Thomas' NHS Foundation Trust. He specialises in the management of prostate and bladder cancers.

He received his oncology training at University College Hospital, London, Great Ormond Street Hospital, London and Mount Vernon Cancer Centre, London

Vinod undertook a nationally funded post CCT fellowship at Mount Vernon Cancer Centre, gaining expertise in modern radiotherapy techniques. He was visiting Brachytherapy Fellow at University of Leuven, Belgium and at University of California, Los Angeles, USA.

He treats solid tumours with radiotherapy, chemotherapy, hormones and biological therapies.

He is actively involved in research and clinical trials and is principal investigator on number of trials.

Vinod is the brachytherapy lead at Guys and St Thomas Hospital. He also led the implementation of image guided interstitial brachytherapy programme for cervical cancer.

He is actively involved in teaching both at undergraduate and postgraduate level and has previously held the position of the College Tutor and the Post graduate faculty lead for Clinical Oncology at Guys and St Thomas' Hospital.

Radiotherapy for prostate cancer and Bladder cancer

Hormone treatment for prostate cancer

SABR for oligo metastatic disease

Research Interests-

high dose rate brachytherapy

cancer imaging

Dr Gregory Wilson is a Consultant Medical Oncologist, based in Manchester at The Christie NHS Foundation Trust. Dr Wilson also sees patients privately at a range of centres, both in the north west and in London. His interests include breast and colorectal cancer and he has a particular focus on metastatic diseases and patients with liver metastases. Dr Wilson is the Lead Clinician for liver-directed therapies and he provides The Harley Street Clinic with both an advisory and visiting clinical service. He works closely with consultant oncology, surgery and radiology colleagues to provide liver-directed therapies for patients of the Harley Street Clinic and The London Oncology Clinic.

He advises on a range of treatment options including Selective Internal Radiation Therapy, Chemotherapy Saturation of the liver and DC beads, a novel drug delivery embolisation system for tumours in the liver. Dr Wilson is a member of the breast and gastrointestinal disease groups of The Christie Hospital and takes an active role in recruiting patients onto national and international clinical research trials of newer treatment regimes.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

• Chemotherapy
• Biological Therapy
• Radiotherapy

• Breast Cancer
• Colorectal Cancer
• Liver Cancer

Dr Ananth Shankar is a Consultant Paediatric and Adolescent Oncologist. He is based at University College London Hospitals NHS Trust and is the Clinical Lead for Adolescent Neuro-oncology. He is an Honorary Senior lecturer in Paediatrics at the ICH/UCL and is a Fellow of the Royal College of Paediatrics and Child Health. He specialises in adolescent neuro-oncology and nodular Lymphocyte Predominant Hodgkin’s Lymphoma [LPHL]

After graduating in medicine from Cailcut Medical College in India, he trained in Paediatric Oncology at Our Lady’s Hospital for Sick Children in Dublin and the Royal Marsden Hospital. He completed a Research Fellowship at Queen Mary and Westfield College in London, with his thesis investigating Paediatric Lymphomas.

Dr Shankar is actively involved in research into Lymphocyte Predominant Hodgkin’s Lymphoma and is the current UK Chief Investigator for the International EuroNet LPHL trial. He is an undergraduate examiner with University College London and is also a clinical and educational supervisor of paediatric oncology trainees.

• Chemotherapy
• Intraventricular Chemotherapy

• Hodgkin Lymphoma 
• Leukaemia 
• Lymphoma 
• Melanoma 
• Myeloma 
• Neuro-endocrine Tumours (NETs) 
• Nodular Lymphocyte Predominant Hodgkin's

Dr Riyaz Shah is a Consultant Medical Oncologist at The Harley Street Clinic and Maidstone and Tunbridge Wells NHS Trust. He specialises in lung and gastrointestinal cancers and malignant mesothelioma.

Dr Shah completed his medical degree at the University of London and obtained a First Class Honours Intercalated BSc in Experimental Pathology. Following this he undertook further medical training at The London Chest Hospital, Hammersmith Hospital, University College London, Guy’s Hospital and The Royal Marsden. In 1997 he became a member of the Royal College of Physicians of London. He undertook a Clinical Research Fellowship with The Imperial Cancer Research Fund to investigate abnormal genes in pancreatic cancer. This work led to him being awarded with a PhD by Imperial College London. Following this, Dr Shah trained to become a specialist in Medical Oncology at The Royal Marsden Hospital and was awarded an ASCO Foundation Merit Award. In 2006 he was appointed Consultant Medical Oncologist at the Kent Oncology Centre.

Dr. Shah is actively involved in training future medical oncologists and has an extensive role in clinical research. He has been a principal investigator on many trials at his centre and has been instrumental in the introduction of immunotherapy into routine clinical practice within Kent. He has served on the NCRI Lung Group, acted as chairman of the Kent Lung Network Lead and continues to be the lead for research at his Cancer Centre. He has been published widely and is regularly asked to speak both nationally and internationally on cancer issues.

• Chemotherapy 
• Immunotherapy 

• Cancer of Unknown Primary 
• Colorectal Cancer 
• Gastro-intestinal Cancers 
• Lung Cancer 
• Thoracic Cancer
• Acute Oncology

Dr Stephanie Gibbs graduated from the Royal Free Hospital Medical School in 1986. She trained in Oncology at the Middlesex Hospital, Mount Vernon Hospital, The Royal London Hospital and St Bartholomew's Hospital. She took up a consultant post at BHR Hospitals NHS Trust in 1998 & worked there for over 21 years. 

She specialises in the treatment of urological and breast cancers using radiotherapy and drug therapies including hormone teatments, chemotherapy, targeted therapies and radioisotope treatment. She is trained in the use of advanced radiotherapy techniques including IMRT, IGRT, the use of SpaceOAR Hydrogel for prostate radiotherapy and SABR.

My hobbies are keeping fit, theatre, and dance.

• Urological cancer
• Breast cancer
• Chemotherapy
• Radiotherapy

• Urological cancers
• Chemotherapy
• Radiotherapy

Dr Teresa Guerrero Urbano is a Consultant Clinical Oncologist and clinical lead for Radiotherapy at Guy’s and St Thomas’ NHS Foundation Trust and King’s College, London. She is honorary Senior Lecturer at the University of Surrey. Her areas of expertise include: Head & Neck Cancer, Non melanomatous skin cancer and Prostate cancer. Dr Guerrero Urbano has previously held senior Consultant Clinical Oncologist and Honorary Senior Lecturer positions at Royal Surrey County NHS Trust, Basingstoke and North Hampshire NHS Foundation Trust, University of Surrey. She was a Senior Research Fellow at University College London and a Clinical Cancer Research Fellow at the Institute of Cancer Research and Royal Marsden Hospital.

Dr Guerrero Urbano completed her oncology training at the Royal Marsden, Royal Surrey County and Guy’s and St Thomas’ Hospitals. She completed her PhD at the University of London in 2008. Dr Guerrero Urbano is joint Module Leader for the Respiratory, Head and Neck module, MSc in Oncology, Institute of Cancer Research. She offers weekly Oncology Seminars at St Luke’s Cancer Centre aimed at doctors, nurses, radiographers and physicists and monthly lectures at the post-graduate Medical School at the University of Surrey. She is a PhD and MD examiner. Her formal research evaluated technical and biological aspects of intensity-modulated radiotherapy at the Institute of Cancer Research/Royal Marsden Hospital. Dr Guerrero Urbano is particularly interested in the use of novel radiation techniques to minimize long-term side effects and the use of chemotherapy and targeted therapy to improve outcomes. Dr Guerrero Urbano has published her research widely and spoken at conferences worldwide.

• Head and neck cancer
• Technical and biological aspects of image-guided radiotherapy (IGRT)
• Intensity-modulated radiotherapy (IMRT)
• Cancer imaging applied to radiotherapy treatments

• Head and neck cancer
• Technical and biological aspects of image-guided radiotherapy (IGRT)
• Intensity-modulated radiotherapy (IMRT)
• Cancer imaging applied to radiotherapy treatments

Dr Peter Harper trained at University College and University College Hospital (MB BS 1970) and has been a leading consultant at Guy's and St Thomas Hospital for over 25 years. He is both an accredited physician and a medical oncologist. One of the four founder partners of the London Oncology Clinic, his vision was of a clinic dedicated solely to cancer treatment offering the highest international standards of care in a state-of-the-art supportive environment, also providing the support including all the ancillary care required by patients and their families.

Author of more than 400 papers and chapters in peer-reviewed publications, he is acknowledged globally for his work in researching new drugs and developing improved forms of cancer treatment. He has been the chair, or has been a member of many international executive committees investigating new approaches to cancer treatment, editorial boards for professional publications and is currently a member of eight pharmaceutical company advisory boards and is a member of sixteen professional bodies from around the world, including board membership of a committee of the American Society of Clinical Oncologists (ASCO).

In 2002 he was awarded the prestigious Cino del Duca Medal in 2004 in recognition of his work in developing new anti-cancer and vaccine therapies. For his role in advising the French Government in strategic cancer care (Board Member French National Cancer Institute), he was appointed a Chevalier of the Legion D'Honneur, a rare distinction for a foreign national. He remains on the board of INCA, the strategic committee for cancer treatment in France, and is currently the Chairman of the Toulouse Cancer Centre and holds the Medaille D'Or of that city.

• Chemotherapy of solid tumours
• Gynaecological cancers
• Gastrointestinal cancers
• Breast cancer
• Lung cancer
• Urological cancers

• Chemotherapy of solid tumours
• Gynaecological cancers
• Gastrointestinal cancers
• Breast cancer
• Lung cancer
• Urological cancers

Dr Ronald Beaney did his undergraduate training in Scotland followed by posts abroad and in the UK. His oncology training was at the Hammersmith Hospital in London where his MD thesis was on the role of positron emission tomography in oncology. He has been a Consultant Clinical Oncologist attached to Guy's and St Thomas and Kings College Hospitals in London. He has produced more than 100 publications on a range of oncological topics.

Dr Beaney's major clinical interests lie in tumours of the brain (gliomas) and pelvis (prostate and gynaecological tumours). He is a member of several UK, European and American Cancer Societies and examiner for the Royal College of Radiologists.

Cyberknife

Gammaknife

• Clinical oncology 
• Gynae
• Prostate
• Bladder
• Central nervous system tumours
• Testicular Cancer
• Renal Cancer
• Ovarian Cancer
• Neuroendocrine Tumours (NETs)